EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs

Qiaoyu Fang, Meng Lu iD, Derong Chen, Liangxu Xie iD, Wenxu Hong iD, Zhang Zhang, Xuqiao Hu iD

Viruses · 2025

DOI: 10.3390/v17121564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Qiaoyu Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Center for Chronic Disease Control and Prevention, Shenzhen Institute of Dermatology, Shenzhen 518020, China. Hauptthemen laut MEDLINE: Drug Repositioning, SARS-CoV-2, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Foundation of China, Medical Scientific Research Foundation of Guangdong Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 virus contains two highly conserved domains, the papain-like protease (PLpro) and main protease (Mpro), which play important roles in virus replication, immune suppression, and the induction of inflammation in host tissue. In this study, we applied small-molecule chip screening, enzymatic assays, SARS-CoV-2 spike pseudotyped virus detection and molecular docking to find potential Mpro or PLpro inhibitors. Two small molecules, oxytocin and risedronate sodium, stood out in drug repurposing. Oxytocin and risedronate sodium were shown to influence the activities of Mpro and PLpro, thereby preventing the virus from replication, which may alleviate SARS-CoV-2 infection. Thus, oxytocin, risedronate sodium, and cephalosporins may expand the drug library for treating coronavirus infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningSARS-CoV-2COVID-19 Drug TreatmentAntiviral AgentsCoronavirus 3C ProteasesCoronavirus Papain-Like ProteasesMolecular Docking SimulationHumansVirus ReplicationCOVID-19

Stichwörter der Autor:innen

MproPLproSARS-CoV-2cephalosporin drugsoxytocin

Substanzen

Antiviral AgentsCoronavirus 3C ProteasesCoronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2

Autor:innen und Institutionen

  • Shenzhen Center for Chronic Disease Control and Prevention, Shenzhen Institute of Dermatology, Shenzhen 518020, China.
  • Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, Jiangsu University of Technology, Changzhou 213000, China.

ORCID-Profile: Meng Lu, Liangxu Xie, Wenxu Hong, Xuqiao Hu

Förderung

  • National Natural Foundation of China
  • Medical Scientific Research Foundation of Guangdong Province of China

Zitieren

APA

Fang, Q., Lu, M., Chen, D., Xie, L., Hong, W., Zhang, Z., & Hu, X. (2025). Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs. Viruses. https://doi.org/10.3390/v17121564

Vancouver

Fang Q, Lu M, Chen D, Xie L, Hong W, Zhang Z, et al. Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs. Viruses. 2025. doi:10.3390/v17121564

BibTeX
@article{Fang2025,
  author = {Fang, Qiaoyu and Lu, Meng and Chen, Derong and Xie, Liangxu and Hong, Wenxu and Zhang, Zhang and Hu, Xuqiao},
  title = {Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17121564}
}
Kostenlos starten →